Advertisement
Home »

Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.

Apr 29, 2024

ABOUT THE EXPERTS

  • Lukas Scheipner

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. l.scheipner@medunigraz.at.

    Department of Urology, Medical University of Graz, Auenbruggerpl. 1, 8036, Graz, Österreich Graz, Austria. l.scheipner@medunigraz.at.

    Andrea Baudo

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.

    Letizia Maria Ippolita Jannello

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.

    Università Degli Studi Di Milano, Milan, Italy.

    Carolin Siech

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt Am Main, Germany.

    Mario de Angelis

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Department of Urology, Comprehensive Cancer Center, Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

    Zhe Tian

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Fred Saad

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Shahrokh F Shariat

    Medical University of Vienna, Vienna, Austria.

    Department of Urology, Weill Cornell Medical College, New York, NY, USA.

    Department of Urology, University of Texas Southwestern, Dallas, TX,, USA.

    Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.

    Alberto Briganti

    Department of Urology, Comprehensive Cancer Center, Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

    Felix K H Chun

    Department of Urology, Comprehensive Cancer Center, Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

    Luca Carmignani

    Università Degli Studi Di Milano, Milan, Italy.

    Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy.

    Ottavio De Cobelli

    Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.

    Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy.

    Johannes Mischinger

    Department of Urology, Medical University of Graz, Auenbruggerpl. 1, 8036, Graz, Österreich Graz, Austria.

    Sascha Ahyai

    Department of Urology, Medical University of Graz, Auenbruggerpl. 1, 8036, Graz, Österreich Graz, Austria.

    Pierre I Karakiewicz

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement